{
    "clinical_study": {
        "@rank": "60518", 
        "arm_group": {
            "arm_group_label": "AVANZ", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This trial is an open, national, multi-centre trial. The main objective of this trial is  to\n      assess the tolerability of the up-dosing phase of AVANZ\u00ae Cupressus arizonica by measurement\n      of related Adverse Events."
        }, 
        "brief_title": "An Open Trial to Assess the Tolerability of AVANZ\u00ae Cupressus Immunotherapy", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Allergic Rhinoconjunctivitis", 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis, Allergic", 
                "Conjunctivitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A documented clinically relevant history of Cupressus arizonica pollen induced\n             allergic rhinoconjunctivitis with or without asthma for at least one year prior to\n             trial entry.\n\n          -  Positive Skin Prick Test (SPT) response to Cupressus arizonica pollen (wheal diameter\n             \u2265 3 mm)\n\n        Exclusion Criteria:\n\n          -  History of severe asthma exacerbation or emergency room visit or admission for asthma\n             in the previous 12 months.\n\n          -  Previous treatment with immunotherapy with Cupressus arizonica pollen extract within\n             the last 5 years (initiation of subcutaneous immunotherapy is acceptable if treatment\n             has been discontinued before reaching maintenance dose; for SLIT 3 months in the last\n             5 years is accepted).\n\n          -  Ongoing treatment with any allergen-specific immunotherapy product.\n\n          -  A history of anaphylaxis with cardiorespiratory symptoms (immunotherapy,\n             exercise-induced, food allergy, drugs or an idiopathic reaction).\n\n          -  A systemic disease affecting the immune system (e.g. insulin-dependent diabetes,\n             autoimmune disease, immune complex disease, or immune deficiency disease whether\n             acquired or not)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02069535", 
            "org_study_id": "AV-X-03", 
            "secondary_id": "2013-004720-11"
        }, 
        "intervention": {
            "arm_group_label": "AVANZ", 
            "intervention_name": "AVANZ Cupressus", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Cupressus arizonica", 
        "lastchanged_date": "February 20, 2014", 
        "number_of_arms": "1", 
        "official_title": "An Open Trial to Assess the Tolerability of AVANZ\u00ae Cupressus Immunotherapy", 
        "overall_contact": {
            "email": "smaes@alk.net", 
            "last_name": "Santiago Mart\u00edn, MsC", 
            "phone": "+34913276127"
        }, 
        "overall_contact_backup": {
            "email": "prnes@alk.net", 
            "last_name": "Pilar Rico, PhD", 
            "phone": "+34913276127"
        }, 
        "overall_official": {
            "affiliation": "Hospital Cl\u00ednico Universitario San Carlos - Madrid", 
            "last_name": "Montserrat Fern\u00e1ndez Rivas, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Frequency of patients with IMP-related AEs", 
            "safety_issue": "Yes", 
            "time_frame": "6 treatment weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02069535"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Frequency of patients with systemic reactions", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks of treatment"
        }, 
        "source": "ALK-Abell\u00f3 A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ALK-Abell\u00f3 A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}